3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
11
Urinary Bladder Neoplasms
6
Carcinoma, Renal Cell
4
Ovarian Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Colonic Neoplasms
2
Urologic Neoplasms
1
Urologic Diseases
1
Ureteral Neoplasms
1
Stroke
1
Stomach Neoplasms
1
Sarcoma
1
Renal Insufficiency, Chronic
1
Recurrence
1
Rectal Neoplasms
1
Pulmonary Disease, Chronic Obstructive
1
Neoplasms
1
Myelodysplastic Syndromes
1
Localized Prostate Carcinoma
1
Leukemia, Myeloid, Acute
1
Kidney Failure, Chronic
1
Hypogonadism
1
Esophageal Neoplasms
1
Disease Progression
1
Diabetes Mellitus
1
Coronary Artery Disease
1
Interventions
Gemcitabine
11
pembrolizumab
8
enfortumab vedotin
8
Specimen Handling
8
Cisplatin
8
Magnetic Resonance Spectroscopy
6
avelumab
5
Carboplatin
5
vinflunine
4
Nivolumab
4
atezolizumab
3
Biopsy
3
cabozantinib
2
Standard of Care
2
Ramucirumab
2
Platinum
2
Ipilimumab
2
Immunoglobulin G
2
Doxorubicin
2
Docetaxel
2
Disulfides
2
CTLA-4 Antigen
2
Bortezomib
2
1,2-diaminocyclohexaneplatinum II citrate
2
vandetanib
1
tocilizumab
1
tamibarotene
1
rucaparib
1
relatlimab
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ureteral Neoplasms
×
Practice Guidelines as Topic
×
Genitourinary
×
Clear all
NCT07087860
2026-05-08
RECIPE-B1
Mayo Clinic
Phase 2
Recruiting
70 enrolled